Suchergebnisse - "DeChanet, Aline"

PubPharm (19)

1

Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) : A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2024

von Terzić, V. | Miantezila Basilua, J. | Billard, N. | +123

2

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy) : A phase 3, randomized, double-blind, placebo-controlled trial

enthalten in: The Journal of infection | 2024

von Hites, M. | Lapique, E. | Massonnaud, C. | +84

3

Ensuring quality control in a COVID-19 clinical trial during the pandemic : The experience of the Inserm C20-15 DisCoVeRy study

enthalten in: Contemporary clinical trials | 2023

von Fougerou-Leurent, C. | Delmas, C. | Saillard, J. | +17

4

Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor : Lessons learnt and challenges from the EU DisCoVeRy clinical trial

enthalten in: Pharmacology research & perspectives | 2023

von Mercier, N. | Belhadi, D. | DeChanet, A. | +122

5

Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials : Experience from EU-Response and conect4children consortia

enthalten in: British journal of clinical pharmacology | 2023

von Terzić, V. | Levoyer, L. | Figarella, M. | +109

6

Management of pharmacovigilance during the COVID‐19 pandemic crisis by the safety department of an academic sponsor : Lessons learnt and challenges from the EU DisCoVeRy clinical trial

enthalten in: Pharmacology Research & Perspectives | 2023

von Mercier, N. | Belhadi, D. | DeChanet, A. | +21

7

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

enthalten in: The Lancet. Infectious diseases | 2022

von Ader, F. | Bouscambert-Duchamp, M. | Hites, M. | +104

8

Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

enthalten in: bioRxiv.org | 2022

von Ader, F. | Bouscambert-Duchamp, M. | Hites, M. | +70

9

An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial

enthalten in: bioRxiv.org | 2022

von Ader, F. | Peiffer-Smadja, N. | Poissy, J. | +55

10

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2021

von Ader, F. | Peiffer-Smadja, N. | Poissy, J. | +56

CommentIn: Clin Microbiol Infect. 2021 Dec;27(12):1716-1717. - PMID 34508887